---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-010093"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2024-02-02T23:59:59+00:00"
generated_at: "2026-06-06T10:03:33.688730+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Samuel J. Reich appointed CEO of SAB Biotherapeutics; remains Executive Chairman

## Summary
- Reich expands role from Executive Chairman to CEO effective February 2, 2024.
- Co-founder Eddie J. Sullivan continues as President and board member, leading operations and R&D.
- Reich co-founded Biscayne Neurotherapeutics (sold to Supernus) and Acuity Pharmaceuticals.
- Company advancing lead candidate SAB-142 for delaying type 1 diabetes progression.

## SEC filing metadata
- accession: 0000950170-24-010093
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2024-02-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000095017024010093/0000950170-24-010093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000095017024010093/sabs-20240130.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-010093
- JSON: https://secwatch.observer/filing/0000950170-24-010093.json
- Plain text: https://secwatch.observer/filing/0000950170-24-010093.txt

## Key facts
- Executive change
  Samuel J. Reich was appointed as Chief Executive Officer at SAB Biotherapeutics, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On January 30, 2024, Samuel J. Reich, age 49, the Executive Chairman of the Board of Directors (the “Board”) of SAB Biotherapeutics, Inc. (the “Company”), was appointed Chief Executive Officer of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1833214/000095017024010093/0000950170-24-010093-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.